Analyst Price Target is $6.00
▲ +244.83% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Connect Biopharma in the last 3 months. The average price target is $6.00, with a high forecast of $7.00 and a low forecast of $5.00. The average price target represents a 244.83% upside from the last price of $1.74.
Current Consensus is
Buy
The current consensus among 3 investment analysts is to buy stock in Connect Biopharma. This Buy consensus rating has held steady for over two years.
Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, focuses on developing therapies to treat T cell-driven inflammatory diseases. The company is building a pipeline of small molecules and antibodies using functional T cell assays to screen and discover potent product candidates against validated immune targets. Its lead product candidate is CBP-201, an antibody to target interleukin-4 receptor alpha in development for the treatment of atopic dermatitis (AD) and asthma. The company's product candidates also comprise CBP-307, a modulator of S1P1 T cell receptor and is in development for the treatment of ulcerative colitis; and CBP-174, a peripherally acting antagonist of histamine receptor 3 in development for the treatment of pruritus associated with skin inflammation. Connect Biopharma Holdings Limited was founded in 2012 and is headquartered in San Diego, California.
Read More